Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,463 | -16,985 | -11,402 | -6,020 | -15,663 |
| Depreciation Amortization | 8,932 | 5,872 | 2,884 | 10,490 | 7,749 |
| Income taxes - deferred | -5,019 | -2,392 | -336 | -2,886 | 0 |
| Accounts receivable | 6,514 | 7,101 | 6,449 | -5,428 | 3,901 |
| Accounts payable and accrued liabilities | 1,757 | 1,169 | 410 | 2,582 | 2,324 |
| Other Working Capital | -1,319 | 2,244 | 3,029 | 7,713 | 13,213 |
| Other Operating Activity | 7,683 | 2,974 | -1,159 | 18,928 | 11,858 |
| Operating Cash Flow | $-3,915 | $-17 | $-125 | $25,379 | $23,382 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 15,059 | -4,517 | 10,270 | -79,062 | -16,812 |
| PPE Investments | -3,026 | -2,370 | -816 | -3,237 | -2,534 |
| Net Acquisitions | N/A | N/A | N/A | -471 | N/A |
| Purchase Sale Intangibles | -74 | -76 | -2 | -204 | -195 |
| Other Investing Activity | -74 | -74 | -2 | -204 | -195 |
| Investing Cash Flow | $11,959 | $-6,961 | $9,452 | $-82,974 | $-19,541 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 4,166 | 2,075 | 690 | 4,181 | 1,396 |
| Debt Repayment | -1,805 | -1,660 | -1,518 | -557 | -418 |
| Common Stock Issued | 240 | 103 | 39 | 1,015 | 877 |
| Common Stock Repurchased | -14,405 | -14,434 | -10,627 | -19,907 | -13,613 |
| Other Financing Activity | -402 | -231 | -129 | -554 | -424 |
| Financing Cash Flow | $-12,206 | $-14,147 | $-11,545 | $-15,822 | $-12,182 |
| Exchange Rate Effect | -1,303 | -2,149 | -1,228 | 4,532 | 3,014 |
| Beginning Cash Position | 98,745 | 98,745 | 98,745 | 167,630 | 167,630 |
| End Cash Position | 93,281 | 75,470 | 95,299 | 98,745 | 162,303 |
| Net Cash Flow | $-5,465 | $-23,275 | $-3,446 | $-68,885 | $-5,327 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,915 | -17 | -125 | 25,379 | 23,382 |
| Capital Expenditure | -3,083 | -2,426 | -849 | -3,525 | -2,631 |
| Free Cash Flow | -6,998 | -2,443 | -974 | 21,854 | 20,751 |